Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vivesto AB ( (SE:VIVE) ) just unveiled an update.
Vivesto AB announced positive preclinical results for Cantrixil in combination with standard treatments for Acute Myeloid Leukemia (AML), demonstrating strong effects and supporting further development. The company has filed a new international patent application to strengthen its intellectual property position and is planning to advance Cantrixil into clinical trials, while exploring partnership opportunities to optimize the development program.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on offering new treatment options for hard-to-treat cancers with significant medical needs and market potential. Their project portfolio includes Cantrixil, aimed at blood cancer, and a veterinary oncology program, Paccal Vet, being evaluated for specific animal cancers. Vivesto’s shares are traded on Nasdaq Stockholm.
Average Trading Volume: 521,025
Technical Sentiment Signal: Sell
Current Market Cap: SEK121.9M
See more data about VIVE stock on TipRanks’ Stock Analysis page.